Cellectis

AGM Information • Jun 30, 2014

PRESS RELEASE

Cellectis SA Combined General Shareholders' Meeting of June 27, 2014

June 30, 2014 – Paris (France) – The Combined General Shareholders' Meeting of Cellectis (Alternext: ALCLS) was held on Friday, June 27, 2014 in Paris, at the Group's headquarters.

At the end of the meeting, during which more than 43,8% of voting rights were exercised, 21 of the 22 resolutions had been adopted.

21 resolutions received more than 96,5% votes in favor. Resolution No. 22, which did not have the Board of Directors' recommendation, was rejected.

In particular, Cellectis' shareholders voted on:

• the approval of the parent company and consolidated financial statements for the fiscal year ended December 31, 2013;
• the renewal as directors the term of office of Ms Annick Schwebig, Mr Pierre Bastid and Mr Laurent Arthaud ;
• the approval of regulated agreements;
• the authorization of a share repurchase plan and the authorization given to the Board of Directors to retire the shares acquired through it;
• various delegations of authority and financial authorizations granted to the Board of Directors.

The full results of the vote can be examined on the company's website (www.cellectis.com).

The Combined General Shareholders' Meeting provided an opportunity for André Choulika, Chairman and Chief Executive Officer, to explain the way in which the Group is positioning itself as a key player in the field of oncology and is playing a full part in the therapeutic revolution taking place in the field of adoptive immunotherapy to fight cancer with T lymphocytes bearing a CAR. In this connection, André Choulika put into perspective the various agreements reached since the beginning of the year.

About Cellectis

Cellectis is a biopharmaceutical company specializing in oncology. Its mission is to develop a new generation of treatments for cancer, based on T-cell engineering. Cellectis has accumulated 14 years' experience in genome engineering – resting on its flagship tools, TALEN™ and meganucleases, and on the pioneering Pulse Agile electroporation technology, in order to create a new generation of immunotherapies to treat leukemia and solid tumors. The adoptive anticancer immunotherapy developed by Cellectis is based on the first allogenic T-cells expressing a chimeric antigenic receptor (CAR) targeting acute and chronic forms of leukemia. CAR technologies are designed to target the surface antigens of cancer cells. These treatments reduce and have the potential to overcome the toxicity associated with current chemotherapies. Thanks to the application of these pioneering genome engineering technologies to the life sciences, the Cellectis group is creating innovative products in many areas that are aimed at a variety of markets. Cellectis is listed on the Alternext market (code: ALCLS). To find out more about us, visit our website: www.cellectis.com

For more information, please contact:

Cellectis Philippe Valachs Phone: +33 (0)1 81 69 16 00 e-mail: media@cellectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.